Drugs / Vistusertib
Trials 33
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT02546661 | Dec 2016 → Mar 2020 overdue | infiltrating bladder urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02619864 | Dec 2016 → Mar 2019 | glioblastoma | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT02780830 | Jun 2016 → Apr 2019 | diffuse large B-cell lymphoma activated B-cell type, relapsed/refractory diffuse large B-cell lymphoma | AstraZeneca | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02640755 | Jan → Dec 2016 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02599714 | Dec 2015 → Mar 2018 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02398747 | Mar 2015 → Apr 2024 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02208375 | Nov 2014 → Jun 2028 expected | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, endometrium adenocarcinoma, fallopian tube carcinoma +4 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02064608 | Oct 2014 → Dec 2016 | prostate cancer | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT01884285 | Jul 2013 → Mar 2019 | castration-resistant prostate carcinoma, non-small cell squamous lung carcinoma, triple-negative breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02193633 | Apr 2013 → Nov 2017 | — | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT01597388 | May 2012 → Aug 2016 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01026402 | Dec 2009 → Aug 2014 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT03366103 | Mar 2018 → Jul 2021 | metastatic malignant neoplasm, small cell lung carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT03205046 | Jun 2017 → Nov 2019 | Richter transformation, diffuse large B-cell lymphoma | Acerta Pharma BV | Terminated | No outcome recorded |
| Phase 1/2 | NCT02813135 | Aug 2016 → Feb 2031 expected | childhood malignant neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02730923 | Apr 2016 → Nov 2019 | endometrial carcinoma, hormone receptor-positive breast cancer, metastatic carcinoma | Centre Leon Berard | Unknown | No outcome recorded |
| Phase 1/2 | NCT02583542 | Jun 2015 → Mar 2020 | non-small cell lung carcinoma, squamous cell lung carcinoma, triple-negative breast carcinoma | Queen Mary University of London | Unknown | No outcome recorded |
| Phase 216 trials · 1 missed | ||||||
| Phase 2 | NCT06727357 | Sep 2019 → Mar 2025 overdue | breast cancer | European Institute of Oncology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03166904 | Mar → Jun 2018 | cancer | Samsung Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT03166176 | Mar → Jul 2018 | cancer | Samsung Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT03334617 | Dec 2017 → Sep 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03071874 | Oct 2017 → Jun 2022 | meningioma | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03106155 | Aug 2017 → May 2018 | small cell lung carcinoma | Samsung Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03061708 | Feb 2017 → Nov 2018 | gastric neoplasm | Samsung Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03082833 | Feb 2017 → Nov 2018 | gastric cancer | Samsung Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT02831257 | Aug 2016 → May 2019 | NF2-related schwannomatosis, meningioma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02752204 | Oct 2015 → Sep 2017 | diffuse large B-cell lymphoma | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02664935 | May 2015 → Nov 2023 | adenocarcinoma, non-small cell lung carcinoma, squamous cell carcinoma | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02403895 | Apr 2015 → Dec 2016 | non-small cell squamous lung carcinoma | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT02117167 | Apr 2014 → Dec 2018 | non-small cell lung carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT02299999 | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02216786 | Jan 2014 → Dec 2021 | estrogen-receptor positive breast cancer | Queen Mary University of London | Completed | Missed primary |
| Phase 2 | NCT01793636 | Feb 2013 → May 2014 | clear cell renal carcinoma | Queen Mary University of London | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02449655 Comparator | Feb 2015 → Jul 2018 | gastric adenocarcinoma | Samsung Medical Center | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2016-04-14 | AstraZeneca | Results AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗
The company will also showcase its continued progress in therapies targeting the genetic drivers of cancer with breaking data on an early-stage mTOR inhibitor that has shown pre-clinical activity in prostate cancer. |
| 2015-04-13 | AstraZeneca | Results AstraZeneca to showcase strong oncology science at American Association for Cancer Research Annual Meeting 2015 astrazeneca.com ↗
Other key data presented at the meeting come from clinical trials exploring combinations of AZD2014, a novel dual TORC1/2 kinase inhibitor with Faslodex in ER+ breast cancer and with chemotherapy in ovarian and lung cancer and preclinical research on combination regimens. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-04-14 | AstraZeneca | AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗ |
| 2015-04-13 | AstraZeneca | AstraZeneca to showcase strong oncology science at American Association for Cancer Research Annual Meeting 2015 astrazeneca.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vistusertib | “Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.” PMID 30016392 ↗ Sep 2018 |
| Known as | AZD2014 | “Module E will investigate the safety and tolerability of MEDI4736 given intravenously, in combination with vistusertib (AZD2014) given orally to patients with MIBC whose...” NCT02546661 ↗25“Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of...” NCT03166904 ↗ “vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.” NCT03106155 ↗ “AZD2014” NCT06727357 ↗ |
| Known as | CC-551 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2336325 ↗ |
| Known as | VISTUSERTIB (AZD2014) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2336325 ↗ |
| Action | Inhibit | “mTor Kinase Inhibitor AZD2014” NCT01026402 ↗ |
| Modality | Small molecule | — CHEMBL2336325 ↗ |
| Route | Oral | “Administered Orally” NCT01597388 ↗ |
| Target | mTOR | “mTor Kinase Inhibitor AZD2014” NCT01026402 ↗ |